Regorafenib- associated panniculitis.
Regorafenib is a second-generation multikinase inhibitor that is approved for the treatment of metastatic colon cancer and advanced gastrointestinal stromal tumors. Hand-foot skin reaction, alopecia, and oral mucositis are well-established side effects of this medication. Herein, we discuss a 60-year-old woman who developed a lobular and septal granulomatous panniculitis after six months of therapy with regorafenib. Biopsy demonstrated focal lobular and septal granulomatous inflammation admixed with septal fibrosis and lobular lymphohistiocytic infiltrate associated with fat necrosis. To our knowledge, regorafenib-induced panniculitis has not been previously described. Increased awareness of this presentation can facilitate more timely diagnosis and treatment.
Ramya
R
Chockalingam
Phyu
P
Aung
Department of Dermatology, University of Texas Medical School at Houston and MD Anderson Cancer Center. apatel11@mdanderson.org.
Anisha B
AB
Patel
D000970:Antineoplastic Agents / Q000009:adverse effects*; D005218:Fat Necrosis / Q000139:chemically induced / Q000473:pathology; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000473:pathology*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007868:Leg Dermatoses / Q000139:chemically induced* / Q000473:pathology; D008875:Middle Aged; D015434:Panniculitis / Q000139:chemically induced* / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D010671:Phenylurea Compounds / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D012867:Skin / Q000473:pathology
D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib